Introduction
============

Sleep is a naturally recurring state and biological phenomenon that fulfills the essential physiological and psychological needs of people. However, over time, the prevalence of sleep disorders (SDs) has increased worldwide. According to a review of epidemiologic studies on SDs, at least 10% of the Western population suffers from SDs that are clinically worthy of attention and crucial to public health [@B1]. The prevalence of SDs was 23.5% in the Japanese population, and a similar result was reported for Asian populations [@B2], [@B3]. Sleep disorders are common in various societies worldwide, particularly in adult populations, and are related to distinct pathologies such as cardiovascular diseases [@B4], diabetes mellitus [@B5], total mortality [@B6], and cancer [@B7]-[@B9]. SDs can either be sleep deprivation or disturbance (short duration of sleep or poor quality of sleep). Sleep disorders are categorized into different classes depending on its nature. The relationship between cancer risk and three categories of sleep disorders are discussed in this paper which are insomnia, parasomnia and obstructive Sleep Apnea (OSA).

According to the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition, Text version (DSM-IV-TR), insomnia is a persistent disorder that can hinder falling asleep, remaining asleep, or both, despite the opportunity for adequate sleep. Working night shifts has been associated with an increased risk of numerous cancers, including breast cancer [@B10]-[@B12] and colorectal adenomas [@B8], a precursor of colorectal cancer. Low sleep efficiency and a lot of sleep disruption are significantly independent risk factors in women with advanced breast cancer [@B13]. The association studies between sleep duration and breast cancer risk suggested that breast cancer risk decreased with increasing sleep duration [@B10], [@B11]. Similarly, 56% lung cancer patients suffered sleep disturbance and that of 60% experienced psychological distress [@B14]. Therefore, sleep disturbance is associated with the risk of developing cancer [@B15]-[@B17] and may serve as a health-threatening factor.

According to the American Sleep Academy, parasomnia is an SD characterized by undesirable physical events or experiences that occur when falling asleep, sleeping, or waking. Parasomnias includes disorders of arousal, rapid eye movement sleep behavior disorder, nocturnal seizures, rhythmic movement disorder, and sleep bruxism [@B18]. This is a classification of SDs involving distinct sleep disruptions that are characterized by confusion, night terrors, and hallucinations. Previous studies indicated that parasomnias were associated with brain tumor [@B19], [@B20]; some of the parasomnias were reported prior to cancer diagnosis [@B20] or after the cancer [@B19]. In addition, Patients with RLS usually have uncomfortable sensations in their legs with compulsion to move, which make them to get up and walk around at night. Restless legs syndrome (RLS), a sensorimotor disorder, was reported as the presenting symptom of multiple myeloma [@B21]. Rapid eye movement sleep behavior disorder (RBD) is frequent in patients with neurodegenerative diseases. RBD was associated with the risk of developing brainstem lymphoma [@B22]. Above evidence indicated that cancer frequently occurs in many individuals with parasomnias.

OSA is classified as disordered breathing during sleep that can cause sleep disturbance or deprivation and is associated with numerous pathologies, such as obesity, type 2 diabetes, the metabolic syndrome, and cardiovascular and neurophysiological diseases [@B23]. Furthermore, OSA is associated with the risk of developing cancer [@B17]. Studies have shown that sleep apnea can impair the health of individuals [@B24], such as by causing cardiovascular complications [@B25]. Notably, sleep apnea has also been a sleep disorder of great clinical relevance because it is a syndrome with a relative incidence and prevalence of 33% of the population [@B24]. The observation is supported by Campos-Rodriguez (2013) in the association between obstructive sleep apnea and cancer incidence in a large multicenter Spanish cohort. This previous study revealed a significant relationship of OSA and an increased risk of cancer but limited to men and patients with ≦ 65 years old [@B26].

Since sleep has a bidirectional relationship with most systems, changes in its pattern can generate negative consequences for the organism. Most researchers have focused on the topic of cancer-induced SDs [@B27]-[@B29] or cross-sectional study [@B30], [@B31] when investigating the relationship between sleep problems and cancer. Few studies that show a relationship between nonapnea SDs and the risks of developing cancer have been published [@B7], [@B32]. In the current study, we investigated specific cancer types in patients with 3 categories of SDs from a nationwide population to examine the association between SDs and the risk of developing cancer. In addition, this study explored the relationship between SDs and cancer in different ae group. Three SDs including insomnia, parasomnias and obstructive sleep apnea focuses on the three classifications which are sleep disorders with physiological hyperarousal, sleep disturbance, and disordered breathing. A large population-based study might help clarify concerns about the risk of SD-induced cancer.

Method
======

Data Sources
------------

In this nested case-control study, 2 million samples were randomly selected from the National Health Insurance Research Database (NHIRD), which contains all of the claims data from the Taiwan National Health Insurance (NHI) program. The NHI program is a government-run system in Taiwan, and approximately 98% of the residents in Taiwan are enrolled in this system. All medical care providers are required to provide outpatient and inpatient services to NHI insurant to claim fees from the NHI program [@B33]. The medical claims information includes data on patient demographics, clinical details (disease and procedure codes according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)), and health utilization (days in hospital, drug use, and charges). The National Health Research Institute (NHRI) maintains the database and releases deidentified secondary data to scientists and clinicians for research purposes. According to the Personal Information Protection Act, the identification of all beneficiaries is encrypted before release for research purposes. The Institutional Review Board of Taipei Medical University in Northern Taiwan approved this study (TMU-JIRB-201210001).

Selection of Cases and Controls
-------------------------------

A cancer case was assembled by searching the outpatient and inpatient claims databases between January 1, 2001 and December 31, 2011 with any cancer diagnostic codes (ICD-9-CM codes 140 to 208) diagnosed by clinical physicians, which were randomly retrieved from the NHIRD. The cancer registry data were also confirmed from the Ministry of Health and Welfare. Moreover, patients aged \< 18 years and who had a history of antecedent cancer before 2001 were excluded, and the cancer cases comprised 68,422 patients. Two controls were frequency matched to each case according to age, sex, and year of cancer diagnosis, and the control group contained 136,844 patients aged \> 18 to limit the study to an adult population. Figure [1](#F1){ref-type="fig"} presents a flow chart for the selection of study participants.

Exposure Ascertainment
----------------------

The exposure of interest included diagnosis of SDs diagnosed by clinical physicians at outpatient visits or during hospitalization with at least 2 service claims. The exclusion criteria for the SD group were (a) a previous diagnosis of SD before 1999, (b) a diagnosis of cancer at any time before the SD, and (c) cases with a latent period less than 2 years, because a latent period of at least 2 years exists between exposure and the development of clinically significant cancer [@B34]. Based on the definition of exclusion, 4,843 measurements of SDs and 30,972 measurements of non-SDs from the cancer cases were obtained. The control group without cancer contained 10,226 measurements of SDs and 64,226 measurements of non-SDs. In this nested case-control study, we divided SD into 3 categories, namely insomnia (ICD-9-CM codes 307.40, 307.42, 307.44, 307.49, and 780.52), parasomnias (ICD-9-CM codes 307.46-307.49), and OSA (ICD-9-CM codes 327.23, 780.51, 780.53, and 780.57), for identifying the types of cancer in patients with these 3 types of SD. Insomniac patients who had comorbidity with parasomnia or OSA were categorized into parasomnia or OSA groups.

Statistical Analysis and Variables of Interests
-----------------------------------------------

The SAS statistical package (SAS systems for Windows, Version 9.2; Cary, NC, USA) was used for performing the analysis, and the *χ*^2^ test was used for analyzing the difference in the demographic information between the study and comparison groups. We separated age into 3 groups: \< 45, 45 to 64, and ≥ 65 years. In addition, average monthly income level was divided into 3 groups: \< US\$640 (NTD 20,000), US\$640 to 1,280 (NTD 20,000-39,999), and ≥ US\$1,281 (NTD 40,000). The Charlson Comorbidity Index (CCI) was divided into 2 groups: \< 3 (low comorbidity) and ≥ 3 (high comorbidity) [@B35]. The CCI is a scoring system which assigns between 1 and 6 points to a range of diseases [@B36]. Four groups were established according to the geographical distributions of the participants: Northern, Central, Southern, and Eastern Taiwan. The urbanization level of the participants\' residences was defined as urban, suburban, and rural. These related factors such as age, gender, income, region, and urbanization were related to sleep disorders [@B7], [@B37]. The incidence density rate was defined as the number of incident cases divided by the sum of the person-time of the at risk population. The univariate Cox proportional hazard regression model was used for computing crude hazard ratios (CHRs) for developing cancer after diagnosis of insomnia, parasomnia, or OSA. The adjusted hazard ratio (AHR) represented the adjusted variables that differed significantly between the study and comparison groups by controlling age, gender, income, region, urbanization, and CCI. A *P* value of \<. 05 was statistically significant.

Results
=======

Table [1](#T1){ref-type="table"} shows the demographic characteristics of patients with cancer and without cancer from 2001 to 2011. After matching for age, gender, and year of cancer diagnosis, significant differences were found between patients with cancer and patients without cancer in terms of region, urbanization, and CCI (Table [1](#T1){ref-type="table"}). Among the 68,422 patients with cancer included in this study, more percentage of the patients with cancer were observed to reside in Southern Taiwan (29.65%) and in urbanized area (54.22%); however, they yielded a higher CCI score (51.25%) compared with the patients without cancer.

Table [2](#T2){ref-type="table"} presents the incidence density rate of cancers in the SD and Non-SD groups among the NHI enrollees. The significantly higher risk of cancer for the participants who aged ≥ 65 years (AHR = 1.22; 95% confidence interval \[CI\]: 1.17-1.27) compared with those in aged \< 45 years. The men had a significantly higher risk (AHR = 1.04; 95% CI: 1.02-1.06) compared with the women patients. The significantly higher risk of cancer for the participants who earned a lower monthly income level (US\$\<640) (AHR = 1.07; 95% CI=1.03-1.11) compared with those in higher income group. In addition, we determined significantly higher risk in patients who resided in Southern Taiwan (AHR = 1.04; 95% CI: 1.02-1.07) than patients who resided in Northern Taiwan.

We observed that the patients with SDs had a higher incidence density rate of cancers than did the patients without SDs (CHR = 1.76; 95% CI: 1.70-1.81). After the confounders of age, gender, income, region, urbanization, and CCI were adjusted, the AHR for cancers in the patients with SDs was significantly higher than that in the comparison group without SDs (AHR = 1.71; 95% CI: 1.66-1.77).

As shown in Table [3](#T3){ref-type="table"}, the incidence, CHR, and the AHR for cancer were both higher in the patients with SDs than in the patients without SDs. This study exhibited significantly increased risks of cancer in patients with SDs compared with the patients without SDs (*P*\<. 001) in each age, sex, and CCI group. As shown in Table [4](#T4){ref-type="table"}, we divided SDs into 3 categories, namely insomnia, parasomnia and OSA, for determining the specific relationship with cancers. After the confounders of age, sex, income, region, urbanization, and CCI were adjusted, significantly increased risks of breast cancer were observed in the patients with insomnia (AHR = 1.73; 95% CI: 1.57-1.90), parasomnia (AHR = 2.76; 95% CI: 1.53-5.00), and OSA (AHR = 2.10; 95% CI: 1.16-3.80) compared with the comparison group. In addition, significantly higher risks of nasal cancer (AHR = 5.96; 95% CI: 2.96-11.99) and the prostate (AHR = 3.69; 95% CI: 1.98-6.89) were observed among patients with OSA as well as significantly increased risks of oral cancer (AHR = 2.71; 95% CI: 1.02-7.24) in patients with parasomnia. Furthermore, patients with insomnia exhibited significantly increased risks of all types of cancer (tracheal, nasal, liver, cervical, oral, colon, lymphatic, thyroid, myeloma, prostate, bladder, and kidney) in this study.

Discussions
===========

This nationwide population-based study of Asian people was to demonstrate the relationship between three specific SDs and the risk of developing cancer. The most valuable finding of this study is that the patients with SDs exhibited a higher risk of breast cancer compared with the patients without SDs. The same increased tendency of developing oral cancer in patients with parasomnias was observed. Moreover, the risk of developing nasal cancer in patients with OSA was extraordinarily high and that of developing prostate cancer was increased. Oral and nasal cancers have seldom been considered to be related with parasomnia and OSA in previous studies.

Patients with SDs had increased risk of cancer than patients without SDs (Table [2](#T2){ref-type="table"}). This result confirmed the findings of internationally collaborative studies [@B10], [@B32], [@B38], [@B39], SDs increased cancer risk might be related to immunosuppression. In this study, patients with insomnia usually have a short duration of sleep while patients with parasomnias and OSA may disturb their sleep; especially the symptoms were present at night. The link between sleep disturbance and the suppression of the immune system might cause malignancies to establish and increase [@B40], [@B41], which have suggested that SDs patients with have an increased risk of breast cancer. However, the mechanisms need to be further explored in the future.

This study recorded a significantly higher risk of prostate cancer in patients with OSA than did the patients without OSA, which was supported by other studies [@B26], [@B42]. However, our results showed that patients with SDs exhibited a higher rate of nasal neoplasm than the comparison group, which was not mentioned in previous studies. Several factors might explain this result; the most crucial reason might be that nasal cancer is considered a virus-related malignancy [@B43], which might be consistent with our hypothesis of an SD-immunosuppression-viral-infection-cancer pathway. When the immune function is influenced, OSA might cause nasal malignancies to increase.

The result of this study showed that the risk of oral cancer was particularly high in patients with parasomnia than did the patients without parasomnia (Table [4](#T4){ref-type="table"}), and this observation is supported by markedly few studies because this is a topic that has not been comprehensively studied. Moreover, epidemiologic studies have shown that SD patients frequently practice unhealthy lifestyles, including smoking and consuming alcohol [@B44], [@B45]. Smoking and consuming alcohol are the main etiologic factors in oropharyngeal cancers[@B46] and, combined with insufficient sleep and a decreasing immune system, might explain the findings of our study. Sleep bruxism (SB), one kind of parasomnias, is that the magnitude of the parafunctional oromotor activity can affect the integrity of the structures of the masticatory[@B47]. Therefore, the pathological effects of SB may alleviate oral cancer. However, the actual reason for this negative consequence remains to further exploring.

Table [2](#T2){ref-type="table"} indicates that risk increases as age increases, and thus, people aged 45 years and older were at a higher risk of developing cancer. The elder is supported by various studies, in which insomnia is referred to as a short duration of sleep [@B8], [@B9], [@B48]. A higher AHR in the male group compared with the female group was observed (AHR = 1.04; 95% CI: 1.02-1.06). The sex difference in cancer susceptibility is one of the most consistent findings in cancer epidemiology and is supported by one previous study [@B49]. In addition, we determined that SD patients with cancers were more likely to have a low income (*P* \<. 001) and high percentage of CCI (*P* \<. 001) because patients with a low income are likely to have inadequate access to medical care and treatment. This outcome is consistent with the research of socioeconomic status [@B50]. Patients with a higher score or CCI score might have a higher range of disease to likely develop cancers compared with the general population, which is also supported by one previous study [@B51].

Our nested case-control study design and detailed information on various potential confounders constitute critical strengths of our study. Nevertheless, several potential limitations must be mentioned. First, we obtained no information on sleep duration, life styles (e.g. smoking, drinking), and family history of cancer, which can be crucial additional factors when assessing the severity of SDs. Second, despite controlling for various potential confounding factors in our research, we cannot exclude the possibility of unknown residual confounders; for instance, family history of cancer might account for these associations. Third, clinical physicians in different medical institutions might use different diagnostic criteria such like OSA. Some might use Apnea-Hypopnea Index \>5 based on an overnight PSG recording as the diagnostic criteria but the others might use sleep apnea screening instruments to diagnose OSA. However, the validity of the diagnosis of SDs and cancer was enhanced by the requirement of at least 2 service claims for ambulatory care within 1 year and diagnosed by clinical physicians. Finally, the latent period of this nested case-control study between prior exposure to SDs and the development of cancer were at least 2 years. Future studies with longer latent durations are warranted to confirm this association and to clarify the association of chronic insomnia with cancer.

In conclusion, this nested case-control study revealed that people diagnosed with one of the 3 aforementioned SDs are at a higher risk of developing cancer than the patients without SDs, specifically breast cancer. The risk of developing nasal cancer and prostate cancer in patients with OSA was extraordinarily high, and the same increased tendency of developing oral cancer in patients with parasomnia was observed. Both men and women aged 45 years (or older) are at a higher risk of cancer when diagnosed with SDs. Further prospective studies, particularly those with more patient-level data are warranted for confirming our findings.
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###### 

Demographic characteristics of patients with cancer and without cancer

  -------------------------------------------------------------------------------------------------------------
  Variable                        Patients with cancer\   Patients without cancer\   *P*value           
                                  (*N* = 68,422)          (*N* = 136,844)                               
  ------------------------------- ----------------------- -------------------------- ---------- ------- -------
  **Age (y)**                     n                       \%                         n          \%      .761

  \< 45                           5,716                   8.35                       11,449     8.37    

  45**-**65                       26,889                  39.30                      53,993     39.45   

  ≥ 65                            35,817                  52.35                      71,402     52.18   

  **Sex**                                                                                               

  Female                          31,206                  45.61                      62,412     45.61   1.000

  Male                            37,216                  54.39                      74,432     54.39   

  **Income (US\$)**                                                                  .555               

  ≥ 1,281 (≥ NT\$40,000)          5,498                   8.04                       10,885     7.95    

  640-1,280 (NT\$20,000-39,999)   9,410                   13.75                      18,645     13.63   

  \< 640 (\< NT\$20,000)          53,514                  78.21                      107,314    78.42   

  **Region**                                                                         \<. 001            

  Northern                        30,197                  44.13                      60,580     44.27   

  Central                         16,283                  23.80                      32,903     24.04   

  Southern                        20,283                  29.65                      39,506     28.87   

  Eastern                         1,659                   2.42                       3,855      2.82    

  **Urbanization**                                                                   . 011              

  Urban                           37,097                  54.22                      73,460     53.68   

  Suburban                        24,146                  35.29                      48, 502    35.44   

  Rural                           7,179                   10.49                      14,882     10.88   

  **CCI**                                                                            \<. 001            

  \< 3                            33,357                  48.75                      71,196     52.03   

  ≥ 3                             35,065                  51.25                      65,648     47.97   
  -------------------------------------------------------------------------------------------------------------

CCI : Charlson Comorbidity Index

###### 

Crude and adjusted hazard ratios for cancers in patients in the SD and Non-SD groups

  ---------------------------------------------------------------------------------------------------------
  Variable                  Cancer                                                
  ------------------------- -------- ----------- ------ ------------------------- -------------------------
  **Age (y)**                                                                     

  \< 45                     3,286    64,310.5    5.11   1.00                      1.00

  45-65                     13,379   247,502.6   5.41   1.12(1.08**-**1.16)\*\*   1.09(1.05**-**1.13)\*\*

  ≥ 65                      19,150   324,403.2   5.90   1.32(1.27**-**1.37)\*\*   1.22(1.17-1.27)\*\*

  **Sex**                                                                         

  Female                    15,707   277,874.9   5.65   1.00                      1.00

  Male                      20,108   358,341.4   5.61   1.03(1.00**-**1.05)\*     1.04(1.02**-**1.06)\*\*

  **Income (US\$)**                                                               

  ≥ 1,281 (≥ NT\$ 40,000)   3,026    56,271.3    5.38   1.00                      1.00

  640-1280\                 5,064    93,957.6    5.39   1.00(0.96**-**1.05)       1.01(0.97**-**1.06)
  (NT\$ 20,000-39,999)                                                            

  \< 640 (\< NT\$ 20,000)   27,725   485,987.4   5.70   1.13(1.09**-**1.18)\*\*   1.07(1.03**-**1.11)\*\*

  **Region**                                                                      

  Northern                  15,762   283,233.0   5.57   1.00                      1.00

  Central                   8.202    147,226.0   5.57   1.02(1.00**-**1.05)       0.99(0.97**-**1.02)

  Southern                  11,021   189,405.0   5.82   1.06(1.03**-**1.08)\*\*   1.04(1.02**-**1.07)\*

  Eastern                   830      16,352.3    5.08   0.93(0.87**-**1.00)\*     0.89(0.83**-**0.95)\*\*

  **Urbanization**                                                                

  Urban                     19,430   344,311.9   5.64   1.00                      1.00

  Suburban                  12,598   223,572.0   5.63   1.01(0.99**-**1.03)       0.99(0.97**-**1.01)

  Rural                     3,787    68,332.4    5.54   1.00(0.96**-**1.03)       0.97(0.94**-**1.01)

  **CCI**                                                                         

  \< 3                      17,536   327,503.1   5.35   1.00                      1.00

  ≥ 3                       18,279   308,713.2   5.92   1.15(1.13-1.18)\*\*       1.01(0.99**-**1.04)

  **Disease Group**                                                               

  Non-SD                    30,972   56,4048.8   5.49   1.00                      1.00

  SD                        4,843    72,167.5    6.71   1.76(1.70**-**1.81)\*\*   1.71(1.66**-**1.77)\*\*
  ---------------------------------------------------------------------------------------------------------

SD= sleep disorder; Non-SD = non-sleep disorder; CHR: crude hazard ratio using univariate cox proportional hazard regression model; AHR: adjusted hazard ratio using cox proportional hazard regression model by controlling for the variables of age, gender, income, region, area, and CCI; CCI: Charlson Comorbidity Index; \*: *P* \<. 05; \*\*: *P* \<. 001; PY=person years; ^†^per 1000 person-years.

###### 

The CHR and AHR for cancers in the SD and Non-SD groups according to the age, gender, and CCI

  Variable       Cancer   Hazard ratio                                    
  -------------- -------- -------------- ------ ------------------------- -------------------------
  **All**        35,815   636,216.3      5.63                             
  Non-SD         30,972   564,048.8      5.49   1.00                      1.00
  SD             4,843    72,167.5       6.71   1.76(1.70**-**1.81)\*\*   1.71(1.66**-**1.77)\*\*
  **Age (y)**                                                             
  \< 45                                                                   
  Non-SD         3,068    61,505.6       4.99   1.00                      1.00
  SD             218      2,804.9        7.77   2.56(2.23**-**2.94)\*\*   2.32(2.02**-**2.68)\*\*
  45-65                                                                   
  Non-SD         11,835   224,047.3      5.28   1.00                      1.00
  SD             1,544    23,455.3       6.58   1.89(1.79**-**1.99)\*\*   1.84(1.74**-**1.94)\*\*
  ≥ 65                                                                    
  Non-SD         16,069   278,495.9      5.77   1.00                      1.00
  SD             3,081    45,907.3       6.71   1.57(1.51**-**1.63)\*\*   1.61(1.55**-**1.67)\*\*
  **Gender**                                                              
  Female                                                                  
  Non-SD         13,077   238,062.7      5.49   1.00                      1.00
  SD             2,630    39,812.2       6.61   1.74(1.66**-**1.81)\*\*   1.71(1.63**-**1.78)\*\*
  Male                                                                    
  Non-SD         17,895   325,986.1      5.49   1.00                      1.00
  SD             2,213    32,355.3       6.84   1.80(1.72**-**1.88)\*\*   1.73(1.65**-**1.81)\*\*
  **CCI**                                                                 
  **CCI** \< 3                                                            
  Non-SD         16,120   308,122.8      5.23   1.00                      1.00
  SD             1,416    19,380.3       7.31   2.12(2.01**-**2.24)\*\*   2.06(1.95**-**2.18)\*\*
  **CCI** ≥ 3                                                             
  Non-SD         14,852   255,926.0      5.80   1.00                      1.00
  SD             3,427    52,787.2       6.49   1.56(1.51**-**2.62)\*\*   1.58(1.52**-**1.65)\*\*

SD = sleep disorder; Non-SD = non-sleep disorder; PY=person years; ^†^per 1000 person-years; CHR: crude hazard ratio using univariate cox proportional hazard regression model; AHR: adjusted hazard ratio using cox proportional hazard regression model by controlling for the variables of age, gender, income, region, area, and CCI; CCI: Charlson Comorbidity Index; CI: confident interval.

\*: P \<. 05; \*\*: P \<. 001

###### 

Incidence and AHR for cancer in the patients of 3 categories of SDs

  Variable           Patients with Insomnia   Patients with Parasomnia   Patients with OSA                                                                                     
  ------------------ ------------------------ -------------------------- -------------------------- --------- ------------- -------------------------- --------- ------------- ---------------------------
  Case               Inc.^†^                  AHR( 95% CI)               Case                       Inc.^†^   AHR, 95% CI   Case                       Inc.^†^   AHR(95% CI)   
  Tracheal Cancer    551                      0.74                       1.61 (1.47**-**1.77)\*\*   8         0.82          1.90 (0.95**-**3.80)       10        0.54          1.38 (0.74**-**2.57)
  Nasal Cancer       67                       0.09                       1.65 (1.27**-**2.14)\*\*   3         0.31          5.00 (1.61**-**15.52)      8         0.43          5.96 (2.96**-**11.99)\*\*
  Liver Cancer       706                      0.95                       1.35 (1.24**-**1.46)\*\*   7         0.72          1.05 (0.50**-**2.20)       16        0.88          1.27 (0.77**-**2.07)
  Breast Cancer      517                      0.69                       1.73 (1.57**-**1.90)\*\*   11        1.13          2.76 (1.53**-**5.00)\*\*   11        0.60          2.10 (1.16**-**3.80)\*
  Cervical Cancer    149                      0.20                       1.25 (1.04**-**1.49)\*     \-        \-            \-                         \-        \-            \-
  Oral Cancer        211                      0.28                       2.07 (1.78**-**2.40)\*\*   4         0.41          2.71 (1.02**-**7.24)\*     6         0.33          1.63 (0.73**-**3.64)
  Colon Cancer       621                      0.83                       1.50 (1.38**-**1.64)\*\*   9         0.93          1.75 (0.91**-**3.37)       14        0.76          1.55 (0.92**-**2.63)
  Lymphatic Cancer   85                       0.11                       2.18 (1.71**-**2.77)\*\*   \-        \-            \-                         \-        \-            \-
  Thyroid Cancer     108                      0.14                       2.05(1.66**-**2.53)\*\*    \-        \-            \-                         3         0.16          2.66 (0.85**-**8.28)
  Brain Cancer       41                       0.05                       1.25(0.90**-**1.75)        \-        \-            \-                         \-        \-            \-
  Myeloma Cancer     66                       0.09                       1.52 (1.16**-**1.98)\*     \-        \-            \-                         \-        \-            \-
  Prostate Cancer    222                      0.30                       2.13 (1.83**-**2.46)\*\*   3         0.31          2.66 (0.86**-**8.28)       10        0.55          3.69 (1.98**-**6.89)\*\*
  Bladder Cancer     166                      0.22                       1.85 (1.56**-**2.19)\*\*   \-        \-            \-                         6         0.33          2.91 (1.30**-**6.50)\*
  Kidney Cancer      157                      0.21                       1.83 (1.53**-**2.18)\*\*   \-        \-            \-                         4         0.22          2.24 (0.84**-**5.98)
  Other Cancer       571                      0.76                       1.38(1.27**-**1.52)\*\*    3         0.31          0.58 (0.19**-**1.79)       10        0.54          1.15 (0.62**-**2.14)

^†^per 1000 person; AHR: adjusted hazard ratio using cox proportional hazard regression model by controlling for the variables of age, gender, income, region, area, and CCI; \*: *P* \<. 05; \*\*: *P* \<. 001

ICD-9-CM codes:

Tracheal cancer: 162, nasal cancer: 147; liver cancer: 155; breast cancer: 174; cervical cancer: 180;

oral cancer: 140, 141, 144, 145, 146, 148; colon cancer: 153, 154; lymphatic cancer: 202; thyroid cancer: 193;

brain cancer: 191; myeloma cancer: 203, 205; prostate cancer: 185; bladder cancer: 188; kidney cancer: 189;

other cancer: 190, 192, 194, 195, 196, 197, 198, 199

\_ : non applicable because of the sample size.
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